Friday, July 30, 2021
News

Monoclonal antibody therapy cuts death risk in Covid-19 patients by 20%

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Washington | Thursday, 2021 2:45:06 AM IST
Administering monoclonal antibody therapy in severe Covid-19 patients, who have not mounted a natural antibody response of their own, can reduce the risk of death by 20 per cent, according to results of a clinical trial.

Treatment with the therapy, which is a combination of two monoclonal antibodies -- Casirivimab and Imdevimab -- was touted as a game changer with its better hold on the deadly Covid pandemic by Indian hospitals.

It has also received an emergency use authorisation (EUA) in India by the Central Drugs Standards Control Organisation (CDSCO) in May.

The therapy, developed by US-based biotechnology company Regeneron, is known as REGEN-COV in the US. The antibodies bind specifically to two different sites on the Covid-19 spike protein, neutralising the ability of the virus to infect cells.

The trial, conducted between September 18, 2020 and May 22, 2021, included 9,785 patients hospitalised with Covid-19.

For patients hospitalised with Covid-19 who do not make their own antibodies to the virus, the antibody therapy can reduce their risk of death and time spent in hospital.

On the other hand, the therapy has no benefit on patients who can make their own antibodies to the virus, said researchers adding it "is also important information given the cost of drugs".

"These results are very exciting. The hope was that by giving a combination of antibodies targeting the SARS-CoV-2 virus, we would be able to reduce the worst manifestations of Covid-19," said Sir Peter Horby, Professor of Emerging Infectious Diseases in the Nuffield Department of Medicine, University of Oxford, and Joint Chief Investigator for the trial, in a statement.

"There was, however, great uncertainty about the value of antiviral therapies in late-stage Covid-19 disease. It is wonderful to learn that even in advanced Covid-19 disease, targeting the virus can reduce mortality in patients who have failed to mount an antibody response of their own," he added.

The therapy has already received a EUA in the US and several EU countries. Regeneron now aims to share new data with regulatory authorities immediately to request that the US EUA be expanded to include appropriate hospitalised patients, it said.

The therapy is also available in India, and hospitals including Medanta in Gurugram, BLK-Max Super Speciality and Sir Gangaram in New Delhi, have successfully implemented the treatment.

--IANS rvt/vd

A

( 396 Words)

2021-06-16-20:52:03 (IANS)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
CSIR DG hails efforts of labs in fight a...
Chouhan meets Mandaviya, discusses Covid...
Karnataka govt urged to reopen primary s...
J&K seen 181 new Covid cases, 175 recove...
3rd Covid vax dose strongly boosts prote...
More than half of German population full...
More...
 
INDIA WORLD ASIA
Four Shiv Sena workers arrested for assa...
Andhra disburses Rs 694 cr to 11L studen...
Punjab to bring law to benefit 31% SC po...
Leopards up from 7,910 to 12,852 in Indi...
Centre offers 27% OBC quota, 10% for EWS...
India constructed 703 km of highways usi...
More...    
 
 Top Stories
Taliban will not be accepted by int... 
Mahesh Babu's first look from 'Sark... 
CSIR DG hails efforts of labs in fi... 
Andhra disburses Rs 694 cr to 11L s... 
Four Shiv Sena workers arrested for... 
Israel inspects NSO Group offices a... 
Lady Gaga's doppelganger at Tokyo 2... 
Punjab to bring law to benefit 31% ...